Atractylenolide II induces cell cycle arrest and apoptosis in breast cancer cells through ER pathway

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• Breast cancer remains a leading cause of cancer-related deaths globally.
• Novel therapeutic agents targeting cancer cell proliferation and survival pathways are urgently needed.
• Atractylenolide II (ATR II) is a compound with potential anti-cancer properties.

Purpose of the Study:

• To investigate the effects of atractylenolide II (ATR II) on breast cancer cell lines (MDA-MB-231 and MCF-7).
• To elucidate the mechanisms underlying ATR II's anti-cancer activity, including apoptosis, cell cycle regulation, and signaling pathways.
• To evaluate ATR II's potential as a therapeutic agent for breast cancer.

Main Methods:

• Cell proliferation was assessed using MTT assays.
• Apoptosis and cell cycle distribution were analyzed by flow cytometry.
• Western blot and luciferase assays were employed to investigate signaling pathways.
• Autodock measurements were performed for validation.

Main Results:

• ATR II significantly inhibited the proliferation of breast cancer cells.
• ATR II induced apoptosis and G2/M-phase cell cycle arrest in cancer cells.
• ATR II modulated ER and NF-κB signaling pathways, indicating anti-inflammatory effects.
• Computational docking studies supported the experimental findings.

Conclusions:

• Atractylenolide II exhibits potent anti-cancer effects against breast cancer cells.
• ATR II functions by inducing apoptosis and cell cycle arrest, and modulating key signaling pathways.
• ATR II demonstrates potential as a novel therapeutic candidate for breast cancer treatment.